SynthesisJAMA network open2023

Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in China: A Systematic Review and Meta-Analysis.

Xingxian Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.